Synopsis
Synopsis
0
JDMF
0
KDMF
0
VMF
0
Australia
0
South Africa
0
Listed Dossiers
Annual Reports
NA
0
API
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. Almogran
2. Almotriptan
3. Axert
1. 181183-52-8
2. Almotriptan Maleate
3. Axert
4. Las 31416 D,l-malate Acid
5. Almotriptan (malate)
6. Almogran
7. Pnu-180638e
8. Almotriptan Malate [usan]
9. Almotriptan D,l-hydrogenmalate
10. Chebi:53781
11. Las-31416 D,l-malate Acid
12. Pjp312605e
13. 181183-52-8(almotriptan Malate)
14. Las-31416-d,l-malate-acid
15. N,n-dimethyl-2-(5-((pyrrolidin-1-ylsulfonyl)methyl)-1h-indol-3-yl)ethan-1-amine 2-hydroxysuccinate
16. 1-(((3-(2-(dimethylamino)ethyl)indol-5-yl)methyl)sulfonyl)pyrrolidine Malate (1:1)
17. 1-(((3-(2-(dimethylamino)ethyl)-1h-indol-5-yl)methyl)sulfonyl)pyrrolidine, Hydroxybutanedioate (1:1)
18. N,n-dimethyl-2-[5-(pyrrolidin-1-ylsulfonylmethyl)-1h-indol-3-yl]ethanamine;2-hydroxybutanedioic Acid
19. Pnu 180638e
20. Unii-pjp312605e
21. Sr-05000001986
22. Axert (tn)
23. Almotriptan Malate (usp)
24. 1-[[[2-(dimethyl-amino)ethyl]-1h-indol-5-yl]methyl]sulfonyl]pyrrolidine Malate
25. Almotriptan Malate (axert)
26. 1-(((3-(2-(dimethylamino)ethyl)-1h-indol-5-yl)methyl)sulfonyl)pyrrolidine, Hydroxybutanedionate (1:1)
27. Mls006010048
28. Schembl221131
29. Almotriptan Maleate [mi]
30. Chembl1200521
31. Dtxsid1044225
32. Almotriptan Malate [vandf]
33. Almotriptan Malate(pnu180638)
34. Hms3651a12
35. Hms3884p05
36. Almotriptan Malate [mart.]
37. Almotriptan Malate [usp-rs]
38. Almotriptan Malate [who-dd]
39. Bcp05632
40. Hy-b0383
41. Mfcd08067740
42. Pnu180638
43. S2096
44. (zznon-labelled)almotriptan-d6 Malate
45. Akos015950790
46. Bcp9000276
47. Ccg-269445
48. Pnu 180638
49. Almotriptan Malate [orange Book]
50. Almotriptan Malate [ep Monograph]
51. Almotriptan Malate [usp Monograph]
52. As-12142
53. Butanedioic Acid, Hydroxy-, Compd. With 1-(((3-(2-(dimethylamino)ethyl)-1h-indol-5-yl)methyl)sulfonyl)pyrrolidine (1:1)
54. Smr004701216
55. Ft-0661519
56. Sw219418-1
57. D02825
58. F14758
59. J-011571
60. Sr-05000001986-2
61. Q27124206
62. 1-(((3-(2-(dimethylamino)ethyl)indol-5-yl)methyl)sulfonyl)pyrrolidine Malate
63. 3-[2-(dimethylamino)ethyl]-5-(pyrrolidin-1-ylsulfonylmethyl )-1h-indole Malate
64. 1-(((3-(2-(dimethylamino)ethyl)-1h-indol-5-yl)methyl)sulfonyl)pyrrolidine Hydroxybutanedioate
65. Butanedioic Acid, 2-hydroxy-, Compd. With N,n-dimethyl-5-[(1-pyrrolidinylsulfonyl)methyl]-1h-indole-3-ethanamine (1:1)
Molecular Weight | 469.6 g/mol |
---|---|
Molecular Formula | C21H31N3O7S |
Hydrogen Bond Donor Count | 4 |
Hydrogen Bond Acceptor Count | 9 |
Rotatable Bond Count | 9 |
Exact Mass | 469.18827151 g/mol |
Monoisotopic Mass | 469.18827151 g/mol |
Topological Polar Surface Area | 160 Ų |
Heavy Atom Count | 32 |
Formal Charge | 0 |
Complexity | 612 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 1 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
1 of 2 | |
---|---|
Drug Name | Almotriptan malate |
Drug Label | AXERT (almotriptan malate) Tablets contain almotriptan malate, a selective 5-hydroxytryptamine1B/1D (5-HT1B/1D) receptor agonist. Almotriptan malate is chemically designated as 1-[[[3-[2-(Dimethylamino)ethyl]-1H-indol-5-yl]methyl]sulfonyl]pyrrolidi... |
Active Ingredient | Almotriptan malate |
Dosage Form | Tablet |
Route | oral |
Strength | 6.25mg; 12.5mg |
Market Status | Tentative Approval |
Company | Teva Pharms |
2 of 2 | |
---|---|
Drug Name | Almotriptan malate |
Drug Label | AXERT (almotriptan malate) Tablets contain almotriptan malate, a selective 5-hydroxytryptamine1B/1D (5-HT1B/1D) receptor agonist. Almotriptan malate is chemically designated as 1-[[[3-[2-(Dimethylamino)ethyl]-1H-indol-5-yl]methyl]sulfonyl]pyrrolidi... |
Active Ingredient | Almotriptan malate |
Dosage Form | Tablet |
Route | oral |
Strength | 6.25mg; 12.5mg |
Market Status | Tentative Approval |
Company | Teva Pharms |
Serotonin Receptor Agonists
Endogenous compounds and drugs that bind to and activate SEROTONIN RECEPTORS. Many serotonin receptor agonists are used as ANTIDEPRESSANTS; ANXIOLYTICS; and in the treatment of MIGRAINE DISORDERS. (See all compounds classified as Serotonin Receptor Agonists.)
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
DRUG PRODUCT COMPOSITIONS
Related Excipient Companies
Excipients by Applications
Global Sales Information
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
77
PharmaCompass offers a list of Almotriptan Malate API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Almotriptan Malate manufacturer or Almotriptan Malate supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Almotriptan Malate manufacturer or Almotriptan Malate supplier.
PharmaCompass also assists you with knowing the Almotriptan Malate API Price utilized in the formulation of products. Almotriptan Malate API Price is not always fixed or binding as the Almotriptan Malate Price is obtained through a variety of data sources. The Almotriptan Malate Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A VA10091 manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of VA10091, including repackagers and relabelers. The FDA regulates VA10091 manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. VA10091 API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of VA10091 manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A VA10091 supplier is an individual or a company that provides VA10091 active pharmaceutical ingredient (API) or VA10091 finished formulations upon request. The VA10091 suppliers may include VA10091 API manufacturers, exporters, distributors and traders.
click here to find a list of VA10091 suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A VA10091 DMF (Drug Master File) is a document detailing the whole manufacturing process of VA10091 active pharmaceutical ingredient (API) in detail. Different forms of VA10091 DMFs exist exist since differing nations have different regulations, such as VA10091 USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A VA10091 DMF submitted to regulatory agencies in the US is known as a USDMF. VA10091 USDMF includes data on VA10091's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The VA10091 USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of VA10091 suppliers with USDMF on PharmaCompass.
A VA10091 CEP of the European Pharmacopoeia monograph is often referred to as a VA10091 Certificate of Suitability (COS). The purpose of a VA10091 CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of VA10091 EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of VA10091 to their clients by showing that a VA10091 CEP has been issued for it. The manufacturer submits a VA10091 CEP (COS) as part of the market authorization procedure, and it takes on the role of a VA10091 CEP holder for the record. Additionally, the data presented in the VA10091 CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the VA10091 DMF.
A VA10091 CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. VA10091 CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of VA10091 suppliers with CEP (COS) on PharmaCompass.
A VA10091 written confirmation (VA10091 WC) is an official document issued by a regulatory agency to a VA10091 manufacturer, verifying that the manufacturing facility of a VA10091 active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting VA10091 APIs or VA10091 finished pharmaceutical products to another nation, regulatory agencies frequently require a VA10091 WC (written confirmation) as part of the regulatory process.
click here to find a list of VA10091 suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing VA10091 as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for VA10091 API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture VA10091 as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain VA10091 and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a VA10091 NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of VA10091 suppliers with NDC on PharmaCompass.
VA10091 Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of VA10091 GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right VA10091 GMP manufacturer or VA10091 GMP API supplier for your needs.
A VA10091 CoA (Certificate of Analysis) is a formal document that attests to VA10091's compliance with VA10091 specifications and serves as a tool for batch-level quality control.
VA10091 CoA mostly includes findings from lab analyses of a specific batch. For each VA10091 CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
VA10091 may be tested according to a variety of international standards, such as European Pharmacopoeia (VA10091 EP), VA10091 JP (Japanese Pharmacopeia) and the US Pharmacopoeia (VA10091 USP).